Show simple item record

AuthorNashwan, A.J.
AuthorYassin, M.A.
AuthorSoliman, A.T.
AuthorDe Sanctis, V.
AuthorIbrahim, M.I.
Available date2023-09-18T09:52:24Z
Publication Date2022
Publication NameActa Biomedica
ResourceScopus
URIhttp://dx.doi.org/10.23750/abm.v93i3.13103
URIhttp://hdl.handle.net/10576/47636
AbstractThe number of COVID-19 vaccine-rich countries that have started COVID-19 third-dose booster programs is growing dramatically despite the lack of robust evidence on the effectiveness, safety, and frequency of the required booster doses that make the individuals/populations immune to COVID-19 infection. Beyond the ethical dilemma, the scarcity of studies on the optimal timing for offering booster doses, eligibility criteria, and if there is any association between premature or delayed administration and the degree of protection against infection. The aim of this mini-review was to collect and analyze published data on this topic in a trial to answer some questions related to the benefits versus the risks of offering frequent boosters of mRNA vaccines for increasing the population immunity against COVID-19 infection considering the current policy of providing SARS-CoV-2 vaccine booster doses in rich countries versus those in relatively poor countries with limited access to vaccination. (www.actabiomedica.it).
Languageen
PublisherMattioli1885
SubjectVaccine Hesitancy
Measles
Anti-Vaccination Movement
TitlemRNA-based COVID-19 Vaccines Booster Dose: BenefitRisks, and Coverage
TypeArticle
Issue Number3
Volume Number93
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record